It has been reported that inhibition of the MAPK pathway activates the JAK2/STAT3 pathway [35], and autocrine Interleukin 6 (IL-6) secretion and subsequent JAK2/ STAT3 activation may represent an unexpected route to overcome targeted inhibition of the MAPK pathway in BRAF mutant cancers [36]. This evidence concerns the gene JAK2 and cancer.